Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 7/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477952 | 0.63 | GNRHR (0.52) | GNRHRLMNA | |
| SCHEMBL6478281 | 0.62 | GNRHR (0.50) | GNRHRLMNA | |
| SCHEMBL5924622 | 0.55 | SMN1; SMN2 (0.34) | LMNA | |
| SCHEMBL3280996 | 0.53 | EPHX1 (0.50) | CYP1A2 | |
| SCHEMBL11015096 | 0.53 | KDM4E (0.46) | LMNA | |
| SCHEMBL14415699 | 0.52 | HTR2A (0.61) | — | |
| SCHEMBL188588 | 0.52 | SLC7A5 (0.55) | CYP1A2CYP3A4LMNA | |
| SCHEMBL188587 | 0.52 | SLC7A5 (0.55) | CYP1A2CYP3A4LMNA | |
| SCHEMBL20514005 | 0.52 | SLC7A5 (0.55) | CYP1A2CYP3A4LMNA | |
| SCHEMBL12610952 | 0.52 | DRD4 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951858-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6673796-B2 | SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CES2 1475/4885CYP1A2 1158/4885CYP3A4 1088/4885 |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, LHCGR, GHRHR | CES2 1350/4885CYP1A2 1120/4885CYP3A4 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.